1Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167(4): 1670-1674
2Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14(6): 1756-1764
3Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated antologous prostate tumor cells engineered to secrete granulocyte macrophage colony stimulating factor usin
4Karashima T, Sweeney P, Slaton JW, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002; 8(5): 1253-1264
5Soulie P, Trump D, Wilding G, et al. ZD 1839 an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK1), is well tolerated in combination with mitoxantrone and prednisone in patients with hormone refractory prostate cancer (HRPC). Ann Oncol
6Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisome in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase Ⅲ study of th European organization for research and treatment of cancer genitourinary g
7Small FJ, Gardncci MA, Wilding G. A phase Ⅰ / Ⅱ dose finding trial of the intravenous injection of CV787, a prostate specific antigen-dependent cytolytic adenovirus in patients with advanced hormone refractory prostate cancer (HRPC). Eur J Cancer 2001;
8Ferlay J, Bray F, Pisani P, et al. Globocan 2000. Cancer incidence, mortality and prevalence worldwide. Version 1.0. IARC Cancer Base No.5. Lyon: IARC Press; 2001
9Sartor O, Weinberger M, Moore a, et al. Effect of prednisone on prostate-specific antigen in patientswith hormine-refractory prostate cancer. Urology 1998; 52(2): 252-256
10Bok RA, Small EJ. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf 1999;20(5): 451-458
4[18]Bohets H,Lavrijsen K,Hendrickx J,et al.Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride:in vitro studies of potential co-medication interactions[J].Br J Pharmacol,2000,129(8):1655-1667.
5[19]Yin H,Racha J,Li S Y,et al.Automated high throughput human CYP isoform activity assay using SPE-LC/MS method:application in CYP inhibition evaluation[J].Xenobiotica,2000,30(2):141-154.
6[20]Mei Q,Tang C,Assang C,et al.Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism[J].J Pharmacol Exp Ther,1999,291 (2):749-759
7[23]Gonzalez D,Elgado P,Florido Lopes F,et al Annallergy[J],1994,73(4):326-328.
